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virus entry, e.g., HIV-1 virus entry, into a mammalian cell via,
for example, administering to a subject an amount of a readthrough mediating agent sufficient to induce exogenous
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METHODS AND PRODUCTS FOR
REAWAKENING RETROCYCLINS

TZM-bl cells were treated with extracts or peptide as indicated in the figure and infected with HIV-1 BaL (6.5 ng/ml
p24) for 24 hr. Infection was measured as percent luciferase
activity compared to cells treated with control cell extract
(Average RLU of control HL60 extract=l 78,200). (B, C)
PM! cells and PBMCs were treated with extracts or peptide
as indicated and infected with HIV-1 BaL (2 ng/ml p24) and
cultured for 5-9 days. Bars represent percent BaL HIV-1
levels in the supematants collected on days 5 (B) and 9 (C).
The amount of p24 in PM! cells treated with control
extract=76.85 ng/ml and in PBMCs treated with control
extracts=55.99 ng/ml. (D) TZM-bl cells were treated with
immunopurified (IP) extracts or peptides as indicated and
infected with BaL HIV-1 (p24=2 ng/ml) for 24 hr. Infection
was quantified as percent luciferase activity compared to cells
treated with control HL60 cell IP extracts (Average
RLU=764,460). Error bars represent SEM. n=3-4, #P<0.004,
*P<0.002, **P<0.0005. (E) CellularviabilityofTZM-bl cells
treated with HL60 acid extracts as indicated was determined
by measuring the reduction of MTT after 24 h (n=3). Bars
represent percent viability as compared to vehicle control and
error bars represent SEM. (F) Cell death was monitored in
PBMCs treated with the acid extracts by a trypan blue exclusion assay on day 9 (n=l).
FIG. 3: Immunofluorescence staining of stably transfected
HL60 cells reveals retrocyclin peptides. (A) Retrocyclin peptides RC-100, RC-101 and RC-101_2K peptides (in duplicates) and (B) RC-100, RC-lOOb, RC-101, protegrin-1 (PG1), rhesus theta defensin-1 (RTD-1 ), and human neutrophil
peptides 1-3 (HNP 1-3) were dotted (0-8 ng/4 µl dot) on a
PVDF membrane and subjected to immuno-dotblot analysis.
(C) Vector control, R1R3 and A1A3 (100,000 cells each)
were fixed onto glass slides and incubated with rabbit antiRC-101 antibody followed by biotinylated goat anti-rabbit
IgG secondary antibody and then stained using FITC-avidin.
Slides were visualized using Zeiss Axiovert 200M microscope system at 40x magnification. The three rows show
FITC staining, DIC and the merged image respectively. Scale
bar represents 20 µm.
FIG. 4: Stably transfected promyelocytic cells produce
retrocyclin. (A) Shows the RP-HPLC trace of A1A3 cell
extract (from 10 8 cells) and 50 µg of synthetic RC-101. (B)
Western blot of A1A3 HPLC fractions (23-28 min) using
rabbit anti-RC-101 antibody. The arrows indicate the multimeric forms of retrocyclin observed in A1A3 fractions. (C)
TZM-bl cells were infected with HIV-1 (p24=2 ng/ml) in the
presence or absence ofpooledA1A3 fractions (final dilution
1:6 in DlO) or 2 µg/ml of RC-101 for 24 hr. Infection was
quantified by luciferase measurement (Average RLU of
Vehicle control with virus=85,450). Error bar represents
SEM and n=3-6, *P<0.0015 **P<0.0001. MALDI-TOF MS
spectra of Lys-C digested (D) synthetic RC-101_2K, (E)
synthetic RC-101 and (F)A1A3 HPLC fraction 26 reveal that
A1A3 cells produce RC-101.
FIG. 5: Aminoglycosides mediate read-through of the premature termination codon within the retrocyclin gene and
promote anti-HIV-1 activity. (A) Shows a schematic representation of the luciferase fusion constructs unrescued
RC-101 and rescued RC-101 along with native retrocyclin
cDNA which encodes the retrocyclin nonapeptide (SEQ ID
NO. 10). (B) HOS-CD4-CCR5 cells cultured in antibiotic
free medium (DlO-) were transfected with unrescued
RC-101 (negative control) or rescued RC-101 (positive control) plasmids along with phRL-CMV vector (transfection
control). The next day transfected cells were treated with PBS
for control cells or aminoglycosides at the indicated concentrations and allowed to grow for 24 hr. Read-through was

FIELD OF THE INVENTION
5

The present invention relates to products and methods for
the restoring the endogenous expression of theta-defensins,
such as retrocyclin polypeptides, in a host cell. The present
invention also relates to products and methods for inhibiting
HIV-1 virus entry into a host cell via, for example, administering to a subject an amount of a read-through mediating
agent sufficient to induce exogenous expression of an amount
of retrocyclin polypeptides in the host cell.
BACKGROUND OF THE INVENTION
Nearly 33 million people are infected with HIV worldwide
[1,2], and despite extensive efforts, there are no effective
vaccines or other countermeasures to protect against HIV
transmission [3]. Previous attempts to find effective anti-HIV
agents have determined that certain synthetic 8-defensins
called "retrocyclins" or "retrocyclin polypeptides" are potent
inhibitors of HIV-1 infection [4-8]. Retrocyclins belong to a
large family of antimicrobial peptides known as defensins, all
of which are cationic, tri-disulfide bonded peptides that have
important roles in innate host defense. Based on the position
of the cysteines and the disulfide bonding pattern, defensins
are grouped into 3 subfamilies: a-defensins, ~-defensins and
8-defensins [9, 10].
8-Defensins such as retrocyclinhave a cyclic peptide backbone, derived from the head-to-tail-ligation of two nonapeptides that each contributes nine amino acids to form the 18
residue mature polypeptide [11]. 8-Defensins are the only
known cyclic peptides in mammals and were originally isolated from rhesus macaque leukocytes and bone marrow [1113]. While 8-defensin peptides, e.g., retrocyclin polypeptides, are produced in old world monkeys and orangutans, in
humans they exist only as expressed pseudogenes [14]. Critically, a premature termination codon in the signal peptide
portion of human retrocyclin mRNA prevents its translation.
The retrocyclin gene is otherwise remarkably intact, showing
89.4% identity with rhesus 8-defensins. Its genetic information was utilized to recreate retrocyclins synthetically and
confirm their activity against both X4 and R5 strains ofHIV-1
[4-7]. To date, however, there has not yet been developed an
agent or process for restoring the mammalian body's ability
to endogenously produce retrocyclin peptides.
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FIG.1: Design ofretrocyclin constructs. (A) Shows a schematic of the 4 constructs (Rl, R3, Al andA3) used for stable
transfections along with native retrocyclin cDNA, which
encodes the retrocyclin nonapeptide (SEQ ID NO. 10). All
constructs have two termination codons at the end to ensure
read-fidelity. Constructs Al and A3 contain additional downstream residues while constructs Rl and R3 lack them. The
two arrows indicate the position at which the two site-directed
mutagenesis (0 l 7Q and R70K) were performed. (B) Shows
the three possible mature retrocyclin peptides that could be
formed from the constructs, homodimers ofRl or Al encoding RC-100 (wild type retrocyclin), heterodimers of Al and
A3 or Rl and R3 encoding RC-101 (single lysine congener)
and homodimers ofR3 or A3 encoding RC-101_2K (double
lysine congener).
FIG. 2: Extracts from HL60 cells stably transfected with
retrocyclin constructs are active against HIV-1 infection. (A)
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determined by measuring luciferase levels. Data is expressed
as fold increase in luciferase expression normalized to renilla
levels. (C) TZM-bl cells grown in DlO- were treated for 30
min with PBS, RC-101 (2.5 µg/ml), RC-100 (2.5 µg/ml) or
aminoglycosides as shown in the figure and infected with
HIV-1 BaL (2 ng/ml p24) for 24 hr followed by luciferase
measurement. Error bars represent SEM. n=3-6, #P<0.007
*P<0.0005 **P<0.0001. (D) TZM-bl cells cultured on cover
slips were treated with PBS (Con) or 10 µg/ml tobramycin
(Tob) and then immunostained with rabbit pre-immune or
anti-retrocyclin serum using a biotinylated secondary antibody FITC-avidin system. (E) Cellular cytotoxicity was
assessed by performing an MTT assay on TZM-bl cells
treated with indicated amount of peptide or aminoglycosides
(n=3). Bars represent percent metabolic inhibition as compared to control (vehicle+virus). (F) TZM-bl cells, treated
with either PBS, tobramycin (10 µg/ml) or RC-100 (2.5
µg/ml), were incubated with preimmune serum or anti-retrocyclin serum as indicated and infected with HIV-1 (p24 of 5
ng/ml). Data is represented as percent infection. Error bars
represent SEM. n=3, +P<0.018 Statistical significance was
determined by two-tailed Student t-test.
FIG. 6: Expression ofretrocyclins in cervicovaginal tissue
model using aminoglycosides. (A) Cervicovaginal tissues
were treated with PBS (Con) or 10 µl tobramycin (Tob) and
incubated with rabbit pre-immune serum or anti-retrocyclin
antibody. The slides were then incubated with biotinylated
goat anti-rabbit IgG secondary antibody and then stained
using FITC-avidin. (B) Cytotoxicitywas determined by measuring Lactate dehydrogenase (LDH) activity inmedia underlying the tissues treated with PBS or tobramycin as indicated.
Bars represent absorbance measured as 490 nm and error bars
represent SEM; n=6. (C) HPLC trace of extracts of tissues
treated with 10 µg/ml tobramycin (Tissue+ Tob) and 20 µg of
synthetic RC-100. (D) RC-100 synthetic peptide (indicated
amounts), HPLC fractions 27-29 of control, tobramycintreated and RC-100 were dotted on a PVDF membrane and
analyzed by immuno-dotblot.
FIG. 7: Verification of stable transfection of retrocyclin
constructs. Analysis of the genomic DNA and RNA of transfected HL60 cells confirms the stable transfection and transcription of rescued retrocyclin constructs respectively. (A)
PCR on genomic DNA template from transfected HL60 cells
shows a 215 bp fragment representing retrocyclin cDNA
construct and a 890 bp fragment of native retrocyclin gene in
the genomic DNA of A1A3 clones but not in the Vector
control (VC) cells. (B, C) Correction of the premature termination codon of retrocyclin cDNA introduces an additional
HpyCH4V restriction site the middle of a 87 bp cDNA fragment. RNA isolated from HL60 cells (control, Rl R3 clones 1
& 2 and A1A3 clones 1 & 2) was used to make cDNA.
Retrocyclin constructs were amplified by PCR using the
cDNA as template and digested using HpyCH4V restriction
enzyme. Electrophoresis of the digested PCR products shows
the expected 87 bp fragment in control cells (B) and the
expected absence of 87 bp fragment in R1R3 and A1A3
clones (C). All the products were also verified by DNA
sequencing.

ducing the modified sequence into a host cell via a delivery
and expression vector (or "delivery vector"). In another
embodiment, the ability to endogenously produce retrocylin
peptides is done via administering an amount of a readthrough mediating agent that is effective to read-through an
existing premature codon to allow for expression of the retrocyclin polypeptide. In this way, utilizing aspects of the
present invention, mammalian host cells may synthesize biologically active retrocyclin polypeptides forthe first time. The
produced biologically active retrocyclin polypeptides may be
utilized as an effective and natural way of combating sexually
transmitted infections (STI's), e.g., HIV-1 infection. For
example, in an aspect of the present invention, there is provided a method of inhibiting sexually transmitted virus entry
into a human cell of a mammalian subject comprising administering an amount of a read-through mediating agent, e.g.,
aminoglycosides effective to produce retrocyclin polypeptides in the mamallian subject.
In accordance with one aspect of the present invention,
there is provided a process for inducing expression of a retrocyclin polypeptide in a host cell. The process comprises
introducing a delivery vector into the host cell, wherein the
delivery vector comprises a polynucleotide having a nucleotide sequence that encodes for a retrocyclin polypeptide
comprising a sequence according to SEQ. ID. NO: 8 or SEQ.
ID. NO: 9, or variants thereof. The introduction of the delivery vector into the host cell results in the expression of the
retrocyclin polypeptide in the host cell.
In accordance with another aspect of the present invention,
there is provided a delivery and expression vector for transfecting a cell with an expression construct that encodes for a
retrocyclin polypeptide. The expression construct comprises
a polynucleotide sequence encoding SEQ. ID. NO: 8 or SEQ.
ID. NO: 9, or variants thereof. The expression construct comprises SEQ. ID. NO: 1, SEQ. ID NO: 2, SEQ. ID. NO: 3, or
SEQ. ID NO: 4, or variants thereof.
In accordance with another aspect of the present invention,
there is provided a method for reducing virus entry into a host
cell of a mammalian subject comprising administering to the
mammalian subject an amount of an expression construct
encoding a retrocyclin polypeptide. The expression construct
comprises a polynucleotide sequence encoding SEQ. ID. NO:
8 or SEQ. ID. NO: 9, or variants thereof.
The terms "variant or variants" as used herein refer to
nucleotide and polypeptide sequences wherein the nucleotide
or amino acid sequence exhibits substantial identity with the
nucleotide or amino acid sequence of the SEQ ID NOs, set
forth herein, preferably 75% sequence identity and most preferably 90-95% sequence identity to the sequences of the
present invention: provided said variant has a biological
activity as defined herein. The variant may be arrived at by
modification of the native nucleotide or amino acid sequence
by such modifications as insertion, substitution or deletion of
one or more nucleotides or amino acids or it may be a naturally occurring variant. The terms "variant" or "variants" also
include homologous sequences which hybridize to the
sequences of the invention under standard or preferably stringent hybridization conditions familiar to those skilled in the
art. Examples of the in situ hybridization procedure typically
used are described in (Tisdall et al., 1999); (Juengel et al.,
2000). Where such a variant is desired, the nucleotide
sequence of the native DNA is altered appropriately. This
alteration can be made through elective synthesis of the DNA
or by modification of the native DNA by, for example, sitespecific or cassette mutagenesis. Preferably, where portions
of cDNA or genomic DNA require sequence modifications,
site-specific primer directed mutagenesis is employed, using

DETAILED DESCRIPTION OF THE INVENTION
The present inventor has surprisingly restored the endogenous expression of the evolutionarily lost retrocyclin
polypeptides in host cells by multiple processes. In one
embodiment, the ability to endogenously produce retrocyclin
polypeptides is done by ablating an existing premature termination codon using site-directed mutagenesis and intro-
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techniques standard in the art. In addition, "variant" or "variants" may encompass amino acid sequences comprising one
amino acid substitution with SEQ. ID. NO: 8 or SEQ. ID. NO:
9 (as set forth herein) or two consecutive amino acid substitutions with SEQ. ID. NO: 8 or SEQ. ID. NO: 9.
In one embodiment, the variants of SEQ. ID. NO: 8 or
SEQ. ID. NO: 9 as set forth herein comprise a polypeptide
having the following sequence:

which encodes the retrocyclin nonapeptide according to SEQ.
ID. NO: 8, or variants thereof, may be represented by SEQ.
ID. NO: 1 or SEQ. ID NO: 2. The nucleotide sequence, which
encodes the retrocyclin nonapeptide according to SEQ. ID.
NO: 9, or variants thereof, may be represented by SEQ. ID.
NO: 3 or SEQ. ID NO: 4.
Turning now to the figures, FIG. lA shows four modified
retrocyclin-expressing constructs (labeled Rl, R3, Al andA3
for convenience). Critically, the expression constructs each
correct a premature termination codon found in the naturally
occurring form of the retrocylin peptide mRNA to enable
expression of the retrocyclin polypeptide. As shown, the termination codon at ((i) 17Q) is replaced with a suitable codon,
such as one encoding for glutamine. Aside from the corrected
premature termination codon ((i) 17Q), all of these constructs (Rl, R3, Al, A3) were engineered to contain two
termination codons at the end of the gene to ensure readfidelity. Constructs with an "R" designation terminate after
the retrocyclin portion of the gene, while constructs with an
"A" designation contain the retrocyclin portion with additional downstream residues that might be critical for translation and/or processing [14, 28].
Constructs with a" 1" designation (Al, Rl) do not have any
additional residues mutated, while constructs with a "3" designation (A3, R3) have the additional Arg~Lys mutation
(R70K) encoding a RC-101 polypeptide. HL60 cells (a
human promyelocytic cell line) were co-transfected by electroporation with either Rl and R3, or Al andA3, and propagated in the presence ofG418 (300 µg/ml) to create stably
transfected cell lines. In another embodiment, host cells may
be transfected with any one ofRl, R3, Al, andA3 individually. Stable transfection was verified by analyzing genomic
DNA and mRNA primers (FIG. 7). Since two different constructs (Rl, R2 and Al, A3) were co-transfected for each
condition, combinatorially it would be possible to generate
three different retrocyclin peptides as illustrated in FIG. lB.
For example, if cells were co-transfected with the Rl and R3
constructs, they could theoretically generate a heterodimer
(R1R3) or homodimers (RlRl or R3R3). Similarly, if cells
were co-transfected with the Al andA3 constructs, they could
theoretically generate a heterodimer (A1A3) or homodimers
(AlAl or A3A3). FIG. lB specifically shows three possible
mature retrocyclin polypeptides that could be formed from
the constructs: homodimers of Rl or Al encoding RC-100
(wild type retrocyclin), heterodimers of Al andA3 or Rl and
R3 encoding RC-101 (single lysine congener) and
homodimers of R3 or A3 encoding RC-101_2K (double
lysine congener).
As shown in FI GS. 2A-2F, the correction of the termination
codon in the retrocyclin constructs restored the translation of
biologically active retrocyclin polypeptides. The infection of
TZM-bl cells with HIV-1 BaL was significantly reduced
when the cells were treated with cellular acid extracts of
R1R3 cells (P<0.004) andA1A3 cells (P<0.002) (FIG. 2A).A
standard tetrazolium MTT assay revealed that the extracts did
not affect cellular metabolism at the concentrations used in
the experiment (FIG. 2E). Addition of A1A3 cell extracts to
HIV-1 infected PM! cells (FIG. 2B) and PBMCs (FIG. 2C)
showed a significant (P<0.002 and P<0.004 respectively)
decrease in the viral titer as compared to cells treated with
control HL60 cell extract. A trypan blue exclusion assay was
performed in PBMCs to monitor cell viability (FIG. 2F).
Next, R1R3 and A1A3 cell extracts were affinity purified
using anti-RC- I 01 antibody and confirmed the antiviral activity in a luciferase-based assay system (FIG. 2D). Interestingly, A1A3 cell extracts were found to be consistently more
active than equivalent amounts of R1R3 cell extract, which
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(I)
Cys
wherein
wherein
wherein
wherein
wherein
wherein

(II)
Cys
(III)
(IV)
(V)
(I) ~ Arg or Lys
(II) ~ Ile, Leu, Glu, or Val
(III) ~ Gly, Ile, Leu, or Val
(IV) ~ Arg or Lys
(V) ~ Gly, Ile, Leu, or Val
(VI) ~ Ile, Leu, Glu, or Val.

(VI)

Cys

The delivery vector may be a viral or non-vector as is
known in the art, including but not limited to, single-stranded
and double-stranded nucleic acid vectors as well as DNA,
RNA, and DNA/RNA chimeric vectors. Exemplary viral vectors include, but are not limited to, adenovirus, herpesvirus,
lentivirus, parvovirus (e.g., AAV), baculovirus and Epstein
Barr Virus vectors. Exemplary non-viral vectors include, but
are not limited to, plasmid, phage, yeast artificial chromosomes (YACs ), Bacterial Artificial Chromosomes (BACs ),
and naked DNA vectors (e.g., by liposomal delivery), or
synthetic nucleotide vectors (e.g., vectors that are generated
by PCR methods or oligonucleotide synthesis, as are known
in the art). In one particular embodiment, the delivery vector
is an adeno-associated virus (AAV) vector, e.g., in the form of
AAV viral particles. In another embodiment, the delivery
vector is a plasmid. Plasmids are "naked" DNA and do not
encode genes necessary to encase the genetic material for
transfer to a new host. The delivery vectors described herein
may be used in both in vitro and in vivo studies.
In one embodiment, the host cell is a mammalian host cell,
e.g., a human host cell. By way of example only, the host cell
may be an epithelial cell or a myeloid cell, including cells
from the spleen, bone marrow, thymus, testis, skeletal
muscle, nasal, nasal mucosa, and cervicovaginal epithelia.
The expression system comprises multiple polynucleotides having a nucleotide sequence that when expressed will
produce a retrocyclin polypeptide as will be explained below.
In one embodiment, the encoded retrocyclin polypeptide is a
homodimer comprising a sequence according to SEQ. ID.
NO: 8, or variants thereof. In a particular embodiment, the
retrocyclin polypeptide comprises a homodimer comprising
two nonapeptides according to SEQ. ID. NO: 8, or variants
thereof. The nucleotide sequence, which encodes the retrocyclin polypeptide according to SEQ. ID. NO: 8, or variants
thereof, may be represented by SEQ. ID. NO: 1 or SEQ. ID
N0:2.
In another embodiment, the encoded retrocyclin polypeptide is a homodimer comprising a sequence according to
SEQ. ID. NO: 9, or variants thereof. In a particular embodiment, the retrocyclin polypeptide comprises a homodimer
comprising two nonapeptides according to SEQ. ID. NO: 9,
or variants thereof. The nucleotide sequence, which encodes
the retrocyclin polypeptide according to SEQ. ID. NO: 9, or
variants thereof, may be represented by SEQ. ID. NO: 3 or
SEQ. ID NO: 4.
In yet another embodiment, the encoded retrocyclin
polypeptide forms a heterodimer comprising a nonapeptide
having a sequence according to SEQ. ID. NO: 8, or variants
thereof, and a nonapeptide having a sequence according to
SEQ. ID. NO: 9, or variants thereof. The nucleotide sequence,
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may suggest a role for the downstream residues in retrocyclin
processing. These results indicated that biologically active
recombinant retrocyclin peptides can be synthesized in
human promyelocytic cells.
The presence of the resulting expressed retrocyclin peptides in promyelocytic cells were confirmed using immunostaining, particularly by the immunofluorescence staining of
stably transfected HL60 cells. As shown in FIGS. 3A and 3B,
for example, immuno-dotblot analyses revealed that an antiRC-101 antibody specifically recognized lysine-containing
human retrocyclin analogs (synthetic RC-101 and RC-101_
2K) and RC-100 (i.e. wild type form) to a lesser extent (FIG.
3A), but not human neutrophil peptides 1-3, or peptides with
very similar tertiary structure including rhesus theta
defensin-1 (RTD-1) and protegrin-1 (PG-1) (FIG. 3B). As
shown in FIG. 3C, an anti-RC-101 antibody was used to
visualize the expressed retrocyclin polypeptides in the stably
transfected HL60 cells by immunofluorescence staining,
which revealed that cells expressing R1R3 heterodimer retrocyclin polypeptides and cells expressing A1A3 retrocyclin
polypeptides were brightly stained as compared to Vector
Control (VC) cells. Slides treated with pre-immune serum
showed no staining (data not shown). The staining of cells
producing A1A3 retrocyclin polypeptides was brighter than
cells expressing R1R3 retrocyclin polypeptides and the morphology of A1A3 was smaller than VC cells.
Thereafter, the presence of the expressed retrocyclin peptides from the cell extracts was confirmed. In particular,
reverse-phase high pressure liquid chromatography HPLC
(RP-HPLC) was utilized to purify the recombinant retrocyclin peptides from stably transfected HL60 cell extracts. FIG.
4A shows the RP-HPLC trace oftheA1A3 heterodimer (RC101) and synthetic RC-101. Synthetic RC-101 was recovered
in fractions collected at 26-28 min. A1A3 HPLC fractions
collected from 23-30 minutes were analyzed on a 16% Tricine-SDS-gel. Control samples did not contain any protein
bands at the expected size while fractions from R1R3 cell
extracts revealed protein bands of about 6 kDa size (not
shown). A1A3 HPLC fractions revealed multiple protein
bands, which were analyzed by western blot (FIG. 4B). The
western blot analysis revealed bands at sizes corresponding to
a monomer, dimer and trimer of retrocyclin. The presence of
multimeric forms ofretrocyclin had previously been uncovered by Daly and colleagues [29].
Furthermore, the RP-HPLC purifiedA1A3 fractions inhibited entry ofHIV-1 BaL in TZM-bl cells (FIG. 4C). The IC 50
of retrocyclin peptides expressed by A1A3 cells (2 µg/ml)
was similar to that of synthetic RC-101 (1.25 µg/ml) [8]. It is
specifically believed that retrocyclins inhibit the fusion of
HIV-1 Env by selectively binding to the C-terminal heptad
repeat region on gp41 blocking 6-helix bundle formation [ 15,
16]. RC-101 is a congener ofretrocyclin with a single arginine to lysine substitution that retains structural and functional
similarity to retrocyclin [4]. RC-101 exhibited enhanced antiHIV-1 activity against over two dozen primary isolates from
several clades [7, 8], and did not induce inflammation or
toxicity in organotypic models of human cervicovaginal tissue [17].
To determine the identity of the retrocyclin peptide
expressed by A1A3-expressing cells (cells transfected with
the Al and A3 sequence and expressing an A1A3 heterodimer), an HPLC fraction 26 (collected at 26 minutes) was
analyzed by mass spectrometric analysis (MALDI-TOFMS). Analysis of the A1A3 fraction revealed peaks with
masses 1889.775 Da (oxidized) and 1895.890 Da (reduced),
which is nearly identical to the expected mass of synthetic
cyclic RC-101 (1889.85 Da and 1895.96 Da respectively;

data not shown) and is in agreement with reduction of the
three disulfide bridges in the molecule. Furthermore, treatment with iodoacetamide yielded mass species of 2238.081
Da for the A1A3 fraction 26 and 2238.071 Da for RC-101
corresponding to the predicted 6-fold-alkylated form of
RC-101 (expected mass=2238.097 Da). Comparison of spectrum of the Lys-C digest of reduced/alkylated synthetic
RC-101_2K (peak at 1123.577 Da; peptide cleaved at two
Lys-Gly bonds; See FIG. 4D), synthetic RC-101 (peak at
2256.097 Da; peptide cleaved at a single Lys-Gly bond;
N-terminal sequence determined as: Gly-Ile-Cys-Arg-; See
FIG. 4E) andA1A3 fraction 26 (peak at 2256.010 Da) suggests that the A1A3 cells are expressing RC-101 (See FIG.
4F). These data confirmed that correctly folded mature retrocyclin polypeptides can be expressed by human cells.
In accordance with another aspect of the present invention,
the inventor has surprisingly found yet another process for
expressing retrocyclin nonapeptides endogenously. In particular, the present inventor has found that the use of specific
read-through mediating agents enable varying degrees oftermination codon read-through to produce retrocyclin nonapeptides. Thus, in one embodiment of the present invention,
there is provided a method for inducing the expression of a
retrocyclin polypeptide in a manimalian host cell having a
naturally-occurring sequence encoding for the retrocyclin
polypeptide, wherein the naturally-occurring sequence has a
premature termination codon. The process comprises inducing expression of the retrocyclin polypeptide in the mammalian host cell via contacting the mammalian host cell with an
amount of a read-through mediating agent effective to readthrough the premature termination codon and allow for
expression of the retrocyclin nonapeptide. By "an amount of
a read-through mediating agent effective to" as used herein, it
is meant an amount effective, at dosages and for periods of
time necessary to achieve the desired result.
In one embodiment, the read-through mediating agent
comprises an aminoglycoside. Thus, the aminoglycoside may
include but is not limited to one or more of amikacin, arbekacin, gentamycin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobramycin, and
apramycin. In a particular embodiment, the aminoglycoside
is one or more of gentamycin, amikacin, or tobramycin. In
another embodiment, the read-through mediating agent is
Ataluren (PTC124®) available from PTC Therapeutics, Inc.,
Plainfield, N.J.
Turning again to the figures, the ability of three exemplary
aminoglycosides (gentamicin, amikacin, and tobramycin)
were tested to induce termination codon read-through ofretrocyclin cDNA. The native retrocyclin gene was fused with a
luciferase reporter at the C-terminus to create 2 constructs:
unrescued RC-101 and rescued RC-101 (positive control) as
shown in FIG. SA. These constructs were transfected into
HOS-CD4-CCR5 cells, grown in the presence of varying
concentrations of aminoglycosides, and the degree of readthrough quantified by measuring luciferase. Application of
tobramycin (10 µg/ml) was the most effective, producing a
26-fold increase in read-through (P<0.0007; FIG. SB).
Having thus established the optimal aminoglycoside concentration required to achieve read-through of retrocylin
cDNA, it was next determined if aminoglycosides could
restore the translation and anti-HIV-I activity of native retrocyclin peptides. HeLa-derived cells lines, such as TZM-bl
cells can natively express retrocyclin mRNA (data not
shown). Aminoglycosides were applied to TZM-bl cells and
challenged them with HIV-1 BaL. It was found that cells
treated with gentamicin and tobramycin significantly
(P<0.0005 andP<0.0001 respectively) inhibited HIV-1 infec-
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tion as compared to untreated cells (FIG. SC). The effect was
modest when compared to inhibition by synthetic peptides.
Cell viability, determined by a tetrazolium based MTT assay,
was not affected by the application of aminoglycosides at the
mentioned concentrations (FIG. SE).
In order to visualize the retrocyclins expressed by application of aminoglycosides, immunostaining was performed.
TZM-bl cells were treated with PBS control or 10 µg/ml
to bramycin and stained with anti-retrocyclin antibody or preimmune serum. Control cells showed no staining while cells
treated with tobramycin revealed brightly stained cells suggesting that aminoglycosides can induce the expression of
retrocyclin peptides (FIG. SD).
TZM-bl cells were incubated with tobramycin (10 µg/ml)
for 24 hr, and then treated the cells with preimmune or antiretrocyclin serum followed by infection with HIV-1. FIG. SF
reveals that cells treated with preimmune serum showed a
modest yet significant reduction in infection as compared to
cells treated with anti-retrocyclin antibodies (P<0.018), suggesting that the antibody inhibited the endogenous retrocyclins. These data confirm that the anti-HIV-1 activity
observed is due to the endogenous retrocyclin peptides
expressed when tobramycin was applied to cells.
Referring to FIGS. 6A-6D, the ability of aminoglycosides
to induce the expression of retrocyclin peptides in an organotypic model cervicovaginal tissue was analyzed. Tissues were
treated apically with tobramycin or control (PBS) for 24 hr
and anti-retrocyclin immunohistochemical analysis was performed. Tissues treated with tobramycin alone and stained
with anti-retrocyclin antibody revealed brightly stained cells
(FIG. 6A) suggesting that production of retrocyclin peptides
is induced upon application of aminoglycosides. Lactate
Dehydrogenase (LDH) activity in the medium underlying the
tissues was performed to determine tissue cytotoxicity. The
LDH assay revealed that application of 10 µg/ml tobramycin
was not cytotoxic to the tissues (FIG. 6B). In addition, treatment of tobramycin did not affect the metabolic activity
adversely, which was determined by an MTT assay performed on one tissue (data not shown).
In order to purify endogenous retrocyclins expressed in the
tissues, reverse-phase HPLC was utilized. FIG. 6C shows an
HPLC trace of control, tobramycin-treated tissue extracts as
compared to synthetic RC-100 peptide. Synthetic RC-100
peptide was recovered in fractions collected at 27-29 minutes.
Corresponding fractions from control and tobramycintreated tissues were analyzed by immuno-dotblot analysis
using the anti-RC-101 antibody. FIG. 6D shows that retrocyclin polypeptides were recovered in the 27-29 min fractions in
tobramycin-treated tissue samples, but not in control tissue
samples. The amount of retrocyclin polypeptides (e.g.,
RC-100) expressed in tobramycin-treated cervicovaginal tissues was estimated by densitometry to be approximately 1.6
µg/tissue. Together these studies show that aminoglycosides
suppress the premature termination codon of retrocyclin transcripts and restore the ability of cervicovaginal tissues to
protect cells from HIV-1.
Accordingly, in another aspect of the present invention,
there is provided a process for inducing the expression of a
retrocyclin polypeptide in a mammalian host cell. The host
cell has a naturally-occurring sequence encoding for the retrocyclin polypeptide, wherein the naturally-occurring
sequence has a premature termination codon. The process
comprises inducing expression of the retrocyclin polypeptide
in the host cell via contacting the host cell with an amount of
a read-through mediating agent effective to read-through the
premature termination codon and allow for expression of the
retrocyclin polypeptide. In one embodiment, the read-

through mediating agent comprises an aminoglycoside. In a
particular embodiment, the aminoglycoside is one or more of
amikacin, arbekacin, gentamycin, kanamycin, neomycin,
netilmicin, paromomycin, rhodostreptomycin, streptomycin,
tobramycin, and apramycin. In one embodiment, the host cell
is a mammalian ho st cell, e.g., a human host cell. The host cell
may be a mucosa! cell, an ocular cell, an epithelial cell, a
cervicovaginal cell, or promyelocytic cells, for example.
In accordance with another aspect of the present invention,
there is provided a process for inhibiting HIV-1 virus entry
into a host cell of a mammalian subject comprising administering to the mammalian subject an amount of a read-through
mediating agent effective to induce expression of a retrocyclin polypeptide in the host cell. In one embodiment, the
read-through mediating agent is an aminoglycoside that is
formulated into a topical composition and administered topically. In another embodiment, the aminoglycoside is administered orally in a suitable formulation, optionally comprising
pharmaceutical carriers and excipients as are known in the art.
In a particular embodiment, the host cell is a female human
cell and the read-through mediating agent is administered
topically to a vaginal mucosa of the subject. In yet another
embodiment, the host cell is a nasal cell or nasal mucosa! cell,
and the read-through mediating agent is administered topically to the nasal mucosa of the subject.
In accordance with another aspect of the present invention,
there is provided a pharmaceutical composition for inhibiting
HIV-1 cell entry comprising an amount of an aminoglycoside
effective to induce expression of a retrocyclin polypeptide in
a mammalian host cell. In one embodiment, the pharmaceutical composition, or a product made therefrom, is formulated
to be consumed orally. In another embodiment, the pharmaceutical composition, or a product made therefrom, is a pharmaceutical, an OTC medicament, an ointment, liquid, cream
or other material suitable for topical application. Alternatively, the pharmaceutical composition may be formulated to
be suitable for oral, rectal, optical, buccal (e.g., sublingual),
parenteral (e.g., subcutaneous, intramuscular, intradermal
and intravenous) and transdermal administration. In one
exemplary embodiment, a product for topical application
may comprise at least 0.01 %, and up to 5.0%, by weight of the
aminoglycoside. Different aminoglycosides are readily commercially available from suitable sources.
In addition, a topical composition may include other cosmetic and pharmaceutical actives and excipients as desired.
Such suitable cosmetic and pharmaceutical agents include,
but are not limited to, antifungals, vitamins, anti-inflammatory agents, antimicrobials, analgesics, nitric oxide synthase
inhibitors, insect repellents, self-tanning agents, surfactants,
moisturizers, stabilizers, preservatives, antiseptics, thickeners, lubricants, humectants, chelating agents, skin penetration
enhancers, emollients, fragrances and colorants.
Further, any embodiment of the pharmaceutical composition may include one or more pharmaceutically acceptable
adjuvants, carriers and/or excipients. Pharmaceutically
acceptable adjuvants, carriers and/or excipients are well
known in the art, for example as described in the Handbook of
Pharmaceutical Excipients, second edition, American Pharmaceutical Association, 1994 (the entirety of which is incorporated by reference herein).
A pharmaceutical composition suitable for oral administration may be prepared in discrete units, such as capsules,
cachets, lozenges, or tablets, each containing a predetermined
amount of the extract; as a powder or granules; as a solution
or a suspension in an aqueous or non-aqueous liquid; or as an
oil-in-water or water-in-oil emulsion. Such compositions can
be prepared by any suitable method of pharmacy, which
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includes the step ofbringing into association the read-through
mediating agent, e.g., an aminoglycoside, and one or more
suitable carriers (which can contain one or more accessory
ingredients as noted above). Generally, the compositions of
the invention are prepared by uniformly and intimately
admixing the aminoglycoside with a liquid or finely divided
solid carrier, or both, and then, if necessary, shaping the
resulting mixture. For example, a tablet can be prepared by
comprising or molding a powder or granules containing the
extract, optionally with one or more accessory ingredients.
Compressed tablets can be prepared by compressing in a
suitable machine, the extracts in the form of a powder or
granules optionally mixed with a binder, lubricant, inert diluents, and/or surface active/dispersing agent(s). Molded tablets can be made by molding, in a suitable machine, the
powdered compound moistened with an inert liquid binder.
Suitable fillers for orally administrable pharmaceutical
compositions, such as sugars, e.g., lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, e.g., tricalcium phosphate or calcium hydrogen phosphate, and also binders such as starch paste using, e.g., com,
wheat, rice or potato starch, gelatin, tragacanth, methylcelluose and/or polyvinylpyrrolidone, and, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, cross linked polyvinyl pyrrolidone, agar or
alginic acid or a salt thereof, such as sodium alginate. Excipients can be flow conditioners and lubricants, for example
silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Tablets,
capsules, or Dragee cores can be provided with suitable,
optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which can comprise gum arabic,
talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutionsin suitable organic solvents
or solvent mixtures, or, forthe preparation of enteric coatings,
solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments can be added to the tablets or dragee
coatings, for example for identification purposes or to indicate different doses of active ingredients.
Other orally administrable pharmaceutical compositions
are dry-filled capsules made, for example, of gelatin, and soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The dry-filled capsules can comprise the
extracts in the form of granules, for example in admixture
with fillers, such as lactose, binders, such as starches, and/or
glicants, such as talc or magnesium stearate, and, where
appropriate, stabilizers. In soft capsules, the extract is preferably dissolved or suspended in suitable liquids, such as fatty
oils, paraffin oil or liquid polyethylene glycols, to which
stabilizers can also be added.
In summary, identifying effective drugs to prevent sexually
transmitted infections and other viral or bacterial infections is
essential for countering the spread of these diseases. Exogenous (synthetic) retrocyclin polypeptides exhibit full activity in the complex environment of vaginal fluid and the peptide is very well tolerated in organotypic human
cervicovaginal tissue models [ 17]. Moreover, HIV-1 evolves
little resistance during continued passaging in the presence of
the peptide [18]. For these and other reasons, retrocyclins
have emerged as potential topical microbicides to protect
against sexually-transmitted HIV-1 infections.
In the present invention, the present inventor has developed
novel and nonobvious human pseudogenes that encode the
demidefensin precursors whose post-translational processing
gives rise to mature retrocyclin peptides are expressed at the
mRNA level in multiple organs, including the spleen, bone

marrow, thymus, testis and skeletal muscle [14] and cervicovaginal epithelia. By transfecting host cells, e.g., human
myeloid cells, ocular cells, or mucosa! cells, with delivery
vectors, e.g., plasmids, comprising containing retrocyclin
constructs without a premature termination codon, it was
demonstrated that the "machinery" needed to process, trim,
splice and oxidize retrocyclin precursors was available in
human cells, e.g., human myeloid or mucosa! cells. Two sets
of expression constructs were transfected into cells: a shorter
form (Rl R3) that terminates at the end of the retrocyclin gene
and a longer form that contains (A1A3) additional 3' untranslated residues (UTR). A1A3 cells expressed higher levels of
retrocyclin peptides as compared to R1R3 cells indicating a
role for additional residues in the translational efficiency of
these peptides. While not wishing to be bound by theory, it is
believed this may due to the fact that the length of the 3'-UTR
regulates translation efficiency [28, 30]. Further, the present
inventor has found that aminoglycoside-treated cells and cervicovaginal tissues may express retrocyclin polypeptides by
suppressing the premature termination codon in their endogenous mRNA transcript.
In one embodiment, the methods, constructs, and pharmaceutical products described herein are effective for preventing
and/or treating sexually transmitted infections (STI' s) including, but not limited to, HIV-1, HIV-2, and other bacterial
infections. For example, in one embodiment, the methods,
constructs, and pharmaceutical products described herein
may be useful in preventing nasal carriage of Staphylococcus
aureus.
Since approximately 30% of inherited disorders may result
from premature termination codon mutations, there has been
tremendous interest and some progress in developing and
applying agents that can read-through premature UAA, UAG
or VGA termination codons [25]. In a sense, human retrocyclin-deficiency is also an inherited disorder, albeit one with an
incidence of 100%. It is caused by a premature termination
codon mutation that occurred after human lineage diverged
from the lineage we share with orangutans, lesser apes and
old world monkeys. Since HIV-1 and other viruses that currently infect humans have evolved in the absence of selective
pressure exerted by retrocyclins, the ability to reawaken this
ancestral molecule could be used to strengthen the innate
immune system's ability to prevent or limit the infections
they now induce.
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HL60 cells [33, 34] obtained from ATCC were cultured in
Iscoves's DMEM with 20% FBS, 100 U/ml penicillin and
100 µg/ml streptomycin (120). TZM-bl cells [35] stably
expressing CD4, CCR5 & CXCR4, has firefly luciferase gene
under the control of HIV-1 promoter (from Dr. Kappes, Dr.
Wu and Tranzyme Inc). TZM-bl, HOS-CD4-CCR5 [36, 37]
(from Dr. Landau), PM! cells [38], (from Dr. Reitz) and
HIV-1 BaL, an R5 tropic strain, were all procured through the
NIH AIDS Research and Reference Reagent program. HIV-1
BaL viral stocks were prepared by infecting PM! cells [18].
Peripheral blood mononuclear cells (PBMC) were isolated
from blood drawn from a healthy HIV-1 seronegative donor
as per the guidelines of the institutional review board of
University of Central Florida. PBMCs were isolated using
Lymphosep® (MP biomedicals LLC, Solon, Ohio), and cultured in RPMI-1640 medium with 10% FBS (RIO) supplemented with 50 Units of IL-2 (R10-50U) and 5 µg/ml of
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phytohemagglutinin (PHA) for 3 days. The cells were then
resuspended in R10-50U at a density of0.8xl 0 6 cells/ml and
grown for 5-6 days.
Cervicovaginal tissues (EpiVaginal™) were obtained from
MatTek Corp., Ashland, Mass. and maintained in proprietary
growth medium as per the company's guidelines. The tissues
were composed of a full-thickness, stratified vaginal-ectocervical layer intermixed with Langehans cells and underlying
lamina propria. The tissues were allowed to grow on transwell
cell culture inserts at the air-liquid interface.

dried and resuspended in 100 µl of0.01 % acetic acid. 100 µg
of synthetic RC-101 peptide was also affinity purified as
positive control (RC-101 IP).
5

Luciferase-Based Infection Assay to Determine
Anti-HIV-1 Activity
10

Example 2
Creation of Retrocyclin Constructs and Stably
Transfected HL60 Cells
Retrocyclin cDNA was amplified from human bone marrow cDNA and cloned into pCRII-TOPO vector (Invitrogen,
Carlsbad, Calif.). Cole et al, Proc Natl Acad Sci USA. 2002
Feb. 19; 99(4): 1813-1818, provides information on the
human retrocyclin gene and protein, which reveals the termination codon 017atthe17 codonposition(seeFIG.1). Two
mutations, Termination codon C017)~Gln (Q.17) and Arg
(R70)~Lys (K70) were introduced, either (2017Q alone
(RC-100) or both (RC-101) using Quick Change® site-directed mutagenesis (Stratagene, LaJolla, Calif.) and subcloned in-frame into the phCMV-luc-FSR vector (Genlantis,
San Diego, Calif.) to generate four constructs Rl, R3, Al and
A3 (FIG. lA). Plasmids Rl and Al encode RC-100 nonapeptide while R3 and A3 encode RC-101 nonapeptide. Constructs Al andA3 have a longer insert that includes additional
downstream residues. HL60 cells (107 cells/400 µl Iscove's
DMEM) were co-transfected with 2 µg each oflinearized Rl,
R3 or Al, A3 or phCMV-luc vector alone, by electroporation
(exponential decay wave mode-280 V; 975 µF) and selected
in I20 medium with 300 µg/ml G418 sulfate. Stable transfectants thus produced were named according to the constructs
used for co-transfection (R1R3, A1A3 or Vector Control:
VC). Presence of these constructs in the cells was verified
using PCR of genomic DNA (FIG. 7A). PCR conditions used
were the following: initial denaturation at 95° C. for 3 min; 30
cycles of95° C. for 1 min, 58° C. for 1 min, 72° C. for 2 min
followed by a final extension at 72° C. for 7 min. Sequences
of the primers used for the PCR reaction are listed in Table 1.
RNA was extracted from 10 6 cells (HL60, VC, R1R3 and
AlA3)usingTRizol (Invitrogen), cleaned withDNaseI (Ambion Inc., Austin Tex.) and cDNA synthesized (iScript™,
BioRad, Hercules Calif.). Expression of recombinant genes
was verified by PCR from the cDNA and subsequent restriction digestion using HpyCH4V (New England Biolabs, Beverly, Mass.) (FIGS. 7B and 7C).

Example 4
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TZM-bl cells (4000 cells/well; 96-well plate) were
infected with HIV-1 Ba L (2-6.5 ng/ml of p24ga~ in the
presence of vehicle (0.01 % acetic acid) or HL60 extracts
(from 0.25xl0 6 control or A1A3 or R1R3 cells) or affinity
purified extracts (from 0.625xl0 6 control HL60 or VC or
R1R3 or AlA3 cells or RC-101 IP diluted 1:32 times) or
RC-101 (20 µg/ml) (positive control) for 24 hr. Treatments
were then removed and the infection was quantified by measuring luciferase using Bright-Gia reagents (Promega, Madison, Wis.) in an LMax luminometer (Molecular Devices,
S=yvale, Calif.). Cytotoxicity and metabolic activity of
cells were verified by a tetrazolium-based MTT assay (R& D
systems, Minneapolis, Minn.) performed on identically
treated cells.
Example 5
Antiviral Infection Assay in Suspension Cells and
HIV-1 p24gag ELISA
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Acid extracts of stably transfected HL60 cells were
vacuum-driedandresuspendedinPBS. PM! cells (10 5 cells)
or PBMCs (10 6 cells) were treated with PBS (vehicle) or
HL60extracts (from 104 cells for PM! and 105 for PBMCs) of
control cells or A1A3 cells or 10 µg/ml of synthetic RC-101
and infected with HIV-1 BaL (2 ng of p24/ml) in 100 µl of
RPMI medium with 20% FBS (R20) for 2 hr. Cells were then
washed with 2 ml of R20, resuspended in fresh medium
containing the treatments and cultured for 5-9 days. Subsequently, on alternate days culture supernatants were collected
and fresh medium with the corresponding treatments was
added. Viability of the cells was measured using trypan blue
exclusion assay. Amount of HIV-1 virus in the culture supernatants was quantified by ELISA for HIV-1 p24gag (Perkin
Elmer, Waltham, Mass.).
Peptides RC-100, RC-lOOb, RC-101, RC-101_2K, synthetic protegrin-1 (PG-1), Rhesus theta defensin-1 (RTD-1)
and human neutrophil peptides 1-3 (HNP 1-3) or unknown
samples were dotted (4 µl dot) as indicated on a 0.22 µm
PVDF membrane (Immobilon-P) that was activated with
methanol and presoaked in TBS. The membrane was then
probed with 1:1000 rabbit anti-RC-101 antibody and developed using Immun™-star HRP reagent (BioRad) [17].

Example 3
Example 6
Acid Extraction and Affinity Purification of
Retrocyclin Peptides
HL60 cells (control, VC, R1R3 andA1A3) were extracted
with 5% acetic acid by vortexing for 20 min, centrifuged for
10 min at 10,000xg, supernatants were then vacuum-dried
and resuspended in 0.01 % acetic acid. HL60 acid extracts
(equivalent of 20x 10 6 cells) were affinity purified using antiRC-101 polyclonal antisera immobilized to a Carbolink™
coupling gel (Pierce Biotechnology Inc. Rockford, Ill.) prepared according to the manufacturer's instructions. Immunopurified samples were desalted using Sep-Pak C-18 cartridges (Waters Corp., Milford, Mass.). The elutes were then

55

Immunostaining of Stably Transfected HL60 Cells
UsingAnti-RC-101 Antibody

60

65

HL60 cells (VC, R1R3 and A1A3) were fixed on slides
(100,000 cells/slide), immersed in 10% Formalin in PBS for
10 min, washed (PBS for 2 min), incubated in Target retrieval
solution (Dako NorthAmerica Inc., Carpinteria, Calif.) for 20
min at 95° C., cooled to 25° C., washed, blocked (2% Goat
Serum, 0.1%Triton-X,0.05% Tween-20, antibody buffer (10
mg/ml BSA/1 mg/ml gelatin/PBS) for 20 min and incubated
in rabbit pre-immune serum or rabbit anti-RC-101 antibody
(1:5000 in antibody buffer) overnight. Slides were washed,
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incubated in biotinylated goat anti-rabbit IgG antibody (1 :20,
000 in 1% goat serum/PBS for 30 min), followed by additional washing and treatment with Fluorescein-Avidin D
(Vector Laboratories Inc.; 1:500 in PBS for 30 min). Cover
slips were mounted using Vectashield fluorescence mounting
medium and visualized using a Zeiss Axiovert 200M microscope system.
Tissues for immunofluorescence staining were fixed in 4%
paraformaldehyde and slides were prepared by Mass Histology (Worcester, Mass.). The slides were deparaffinized,
washed with TBS, and stained with anti-retrocyclin or preimmune serum and immunostained the same way as cells.
The slides were then visualized on a Zeiss Axiovert 200M
microscope system with 450 ms exposure time for all slides.

ZipTip (Millipore Corp., Billerica, Mass.) and subjected to
Edman degradation on cLC-Procise sequencer (Applied Biosystems, Forest City, Calif.).
5

Aminoglycoside Mediated Read-Through of
Termination Codon
10

15

Example 6
Separation of Proteins from Stably Transfected
HL60 Extracts Using Reverse-Phase HPLC
20

Acid extracts from control HL60 and A1A3 cells (equivalent oflOOxl 0 6 cells) were separated by RP-HPLC using the
Alliance HT Waters 2795 Separations Module on a C 18 Column equilibrated in solvent A (aqueous 0.1 % TFA). Elution
was done with a gradient of0-95% solvent B (0.08% TFA in
acetonitrile), for 75 min, at 1 ml/min. Collected fractions (1
ml each) were vacuum dried and reconstituted in 100 µl of
0.01 % acetic acid. Synthetic RC-101 peptide (control) was
recovered from the fractions eluting at 26-28 min. A1A3
HPLC fractions (#23-28) were electrophoresed on a 16%
Tricine-SDS gel and electro blotted on a 0.22 µm PVDF membrane at 180 mA for 22 min. The western blot membrane was
then processed as described [17] and developed with ChemiGlow reagent (Alpha Innotech, San Leandro, Calif.). AlA3
RP-HPLC fractions (27-30 min) were pooled and the concentration was determined to be (2.13 ng/µl) by densitometry
measurements using Quantity one 1-D analysis (BioRad). A
luciferase-based assay was used to verify the activity ofA1A3
HPLC fractions (diluted 3 times in DlO) against HIV-1 BaL
(2 ng p24/ml).
MatTek cervicovaginal tissues treated with PBS (control)
or 10 µg/ml tobramycin were extracted with T-PER® reagent
(Pierce Biotechnology Inc. Rockford, Ill.) and separated by
RP-HPLC. 20 µg of synthetic retrocyclin (RC-100) was also
separated as a positive control. Synthetic RC-100 was eluted
in fractions collected at 27-29 min. Tissue samples eluted at
27-29 min were vacuum-dried to near dryness and resuspendedin 100 µl of0.01 % acetic acid. HPLC fractions (27-29
min) of MatTek tissue extracts (control or tobramycintreated) and synthetic RC-100 were analysed by immunodotblot analysis.

25
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A1A3 HPLC Fraction 26, RC-101 and RC-101_2K were
reduced, alkylated and treated with Lys-C protease for 30 min
before analyzing by mass spectrometry. In brief, 20 mM Tris
[2-carboxyethyl]phosphine (TCEP) was used to reduce (30
min at 25° C.) the samples, alkylated by incubating the
samples with iodoacetamide (60 mM; 45 min at 25° C.; pH
8-9) followed by digestion with Lys-C (Waka Chemicals,
Richmond, Va.; 30 min at 37° C.) and subjected to MALDITOF-MS analysis using a model 4700 Proteomics Analyzer
(Applied Biosystems, Foster City, Calif.) as described previously [39]. Lys-C digested RC-101 was desalted using C18

Wildtype and mutant retrocyclin cDNAs were subcloned
into phCMV-luc-FSR vector to create unrescued RC-101 and
rescued RC-101 C-terminal luciferase fusion constructs, and
verified by sequencing. HOS-CD4-CCR5 cells were cultured
in antibiotic free growth medium (DlO-) and co-transfected
with 0.5 µg ofunrescued or rescued (positive control) RC-101
plasmids along with 0.1 µg of phRL-CMV vector (transfection control containing renilla luciferase gene) using Effectene transfection reagent (Qiagen, Valencia, Calif.). The next
day cells were treated for 24 hr with the appropriate aminoglycoside (40 µg/ml amikacin or 5 µg/ml gentamicin or 10
µg/ml tobramycin) or DlO- for control cells. Read-through
was determined by measuring luciferase and renilla levels
using a dual luciferase assay (Promega Corp., Madison,
Wis.).
TZM-bl cells (4000 cells/well; 96 well plate) were cultured
in DlO- and treated with vehicle (PBS buffered DlO-) or
peptides RC-101 or RC-100 (2.5 µg/ml each) as positive
control or aminoglycosides as before for 30 min followed by
infection with HIV-1 BaL (p24 of 2 ng/ml) at 37° C. for 24 hr.
Subsequently, viral infection was quantified by measuring
luciferase levels using Bright-Gia reagents (Promega). Cellular metabolism was monitored by measuring reduction the
ability of cellular dehydrogenases to reduce MTT to formazan (R& D Systems).
TZM-bl cells were cultured on coverslips and treated with
PBS control or 10 µg/ml oftobramycin for 24 hr. The coverslips were then processed for immunofluorescence staining
with anti-retrocyclin (rabbit anti-RC-101 antibody) or preimmune serum as described above.
For antibody-mediated neutralization experiments, TZMbl cells (4000 cells/well; 96 well plate) were cultured in Dlomedium and treated with vehicle (PBS) or 10 µg/ml oftobramycin for 24 hr. The next day, cells were treated with either
rabbit preimmune or anti-retrocyclin serum diluted 1:10 in
DlO- medium containing tobramycin or RC-100 (2.5 µg/ml).
Two hours later the cells were infected with HIV-1 BaL (p24
of 5 ng/ml) at 37° C. for 24 hr. Viral infection was quantified
as described above. An MTT assay was performed to confirm
that the treatments were not cytotoxic (data not shown).

50

Example 9

Example 7
Mass Spectrometric Analysis

Example 8

Application of Aminoglycosides to Organotypic
Cervicovaginal Tissue Model
55

60

65

Cervicovaginal tissues were treated topically with 100 µl of
PBS (control; n=4) or with 10 µg/ml oftobramycin (n=8) for
24 hr. Viability was assessed on control and tobramycintreated tissue (n=l) using MTT assay kit (MatTek Corp.,
Ashland, Mass.). Cytotoxicity was measured by quantifying
lactate dehydrogenase (LDH) activity in the underlying
medium collected 24 hr after treatment with PBS or tobramycin by using CytoTox96 non-radioactive cytotoxicity assay
kit (Promega Corp., Madison, Wis.).
Various modifications and variations of the described
methods and system of the invention will be apparent to those
skilled in the art without departing from the scope and spirit of
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the invention. Although the invention has been described in
connection with specific preferred embodiments, it should be
understood that the invention as claimed should not be unduly
limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention
which are obvious to those skilled in molecular biology or
related fields are intended to be within the scope of the claims.
The teachings of all cited references are incorporated herein
in their entirety to the extent not inconsistent with the teachings herein.
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SEQUENCE LISTING
SEQ.
SEQ.
SEQ.
SEQ.
SEQ.
SEQ.
SEQ.

NO,
NO,
NO,
NO,
NO,
NO,
NO,

ID.
ID.
ID.
ID.
ID.
ID.
ID.
1
61
121
181
241
301
361
421
481

8,Arg Cys Ile Cys Gly Arg Gly Ile Cys
9,Arg Cys Ile Cys Gly Lys Gly Ile Cys
1,CGT TGT ATT TGT GGT CGT GGT ATT TGT
2,CGC TGC ATC TGC GGC CGC GGC ATC TGC
3,cGT TGT ATT TGT GGT AAA GGT ATT TGT
4,cGC TGC ATC TGC GGC AAG GGC ATC TGC
5 DNA
ggagacccgg gacagaggac tgctgtctgc cctccctctt
tctgtcaccc cagccatgag gaccttcgcc ctcctcactg
ctgtaggctc aggcggagcc acttcaggca agagctgatg
cctggagcag atgatcagga aatggctcat gcctttacat
ccgctttcag actcagcgag aggcttgagg tgcatttgcg
ttataacgtc gctttgggtc ctgcgccttt cgtggtacac
tgagcttgca gaatcaagaa acataagctc agaatttact
ttgttactcc tgtaccttgt cctccatttc cttttctcat
caagatttct ctcttt

cactctgcct accttgagga
ccatgcttct cctggtggcc

aagctgcagc ccaggagcag
ggcatgaaag tgccgctctt
gaagaggaat ttgccgtttg
tccaccggat ctgctgccgc
ttgagagtta aaagaaattc
ccaaaataaa taccttgttg

TABLE 1
Primers used for verification
of retrocyclin constructs.

35

Primer
Name

DEFT Fwd

Sequence

TCCTCACTGC
CATGCTTCT

40

TTATAACAAAC AF526271.1
GGCAAATTCCT
AF355799

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 10
SEQ ID NO 1
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocyclin

<400> SEQUENCE, 1
cgttgtattt gtggtcgtgg tatttgt

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocylin

AF526271.1
AF355799

DEFT Rev

<210>
<211>
<212>
<213>
<220>
<223>

Accession
Number

27

Primer
Location Template

29-47

Genomic
DNA
92-110 cDNA

897-918 Genomic
DNA
285-306 cDNA
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22
-continued

<400> SEQUENCE, 2
cgctgcatct gcggccgcgg catctgc

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 3
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocylin

<400> SEQUENCE, 3
cgttgtattt gtggtaaagg tatttgt

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 4
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocylins

<400> SEQUENCE, 4
cgctgcatct gcggcaaggg catctgc

27

<210> SEQ ID NO 5
<211> LENGTH, 496
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Retrocylin
<400> SEQUENCE,

5

ggagacccgg gacagaggac tgctgtctgc cctccctctt cactctgcct accttgagga

60

tctgtcaccc cagccatgag gaccttcgcc ctcctcactg ccatgcttct cctggtggcc

120

ctgtaggctc aggcggagcc acttcaggca agagctgatg aagctgcagc ccaggagcag

180

cctggagcag atgatcagga aatggctcat gcctttacat ggcatgaaag tgccgctctt

240

ccgctttcag actcagcgag aggcttgagg tgcatttgcg gaagaggaat ttgccgtttg

300

ttataacgtc gctttgggtc ctgcgccttt cgtggtacac tccaccggat ctgctgccgc

360

tgagcttgca gaatcaagaa acataagctc agaatttact ttgagagtta aaagaaattc

420

ttgttactcc tgtaccttgt cctccatttc cttttctcat ccaaaataaa taccttgttg

480

caagatttct ctcttt

496

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 19
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE,
tcctcactgc catgcttct

<210>
<211>
<212>
<213>

19

SEQ ID NO 7
LENGTH, 22
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 7
ttataacaaa cggcaaattc ct

<210> SEQ ID NO 8
<211> LENGTH, 27

22
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24
-continued

<212>
<213>
<220>
<223>

TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocylin

<400> SEQUENCE, 8
Ala Arg Gly Cys Tyr Ser Ile Leu Glu Cys Tyr Ser Gly Leu Tyr Ala
1
5
10
15
Arg Gly Gly Leu Tyr Ile Leu Glu Cys Tyr Ser
20
25

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 27
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Retrocylin

<400> SEQUENCE, 9
Ala Arg Gly Cys Tyr Ser Ile Leu Glu Cys Tyr Ser Gly Leu Tyr Leu
1
5
10
15
Tyr Ser Gly Leu Tyr Ile Leu Glu Cys Tyr Ser
20
25

<210>
<211>
<212>
<213>

SEQ ID NO 10
LENGTH, 9
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE,

10

Arg Cys Ile Cys Gly Arg Gly Ile Cys
1
5

The invention claimed is:
1. A method for inducing the expression of a retrocyclin

polypeptide to reduce infection in a mammalian vaginal
mucosa! cell having a naturally-occurring sequence encoding
for the retrocyclin polypeptide, the naturally-occurring
sequence having a premature termination codon, the method
comprising:
inducing expression of the retrocyclin polypeptide in the
mammalian vaginal mucosa! cell to reduce infectious
agent entry into the mucosa! cell by contacting the vaginal mucosa! cell with an amount ofa read-through mediating agent effective to read-through the premature termination codon and allow for expression of the
retrocyclin polypeptide;

40

45

wherein the read-through mediating agent comprises at
least one of gentamicin and tobramycin.
2. A method for reducing infectious agent entry into a
vaginal mucosa of a mammalian subject having a naturallyoccurring sequence encoding for a retrocyclin polypeptide,
the naturally-occurring sequence having a premature termination codon, the method comprising:
administering to the vaginal mucosa of the manimalian
subject an amount of a read-through mediating agent
effective to read-through the premature termination
codon to induce expression of the retrocyclin polypeptide that reduces infectious agent entry into the vaginal
mucosa, wherein the read-through mediating agent
comprises at least one of gentamicin and tobramycin.

* * * * *

